text:
Quotes & Info
|BPTH > SEC Filings for BPTH > Form 10-Q on 14-Nov-2013
|All Recent SEC Filings
Quarterly Report
When you read this section of this Quarterly Report on Form 10-Q, it is important that you also read the unaudited financial statements and related notes included elsewhere in this Form 10-Q and our audited financial statements and notes thereto included in our Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2012. This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations, and intentions. We use words such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "believe," "intend," "may," "will," "should," "could," and similar expressions to identify forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the matters discussed under the caption "Risk Factors" in "Item 1, BUSINESS" in our Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2012, and other risks and uncertainties discussed in filings made with the Securities and Exchange Commission. See "Note Regarding Forward Looking Statements" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012 for additional discussion regarding risks associated with forward-looking statements.
Bio-Path Holdings, Inc. (together with its subsidiary, "Bio-Path" or the "Company" or "we," "us" or "our") is a development stage company with its lead cancer drug candidate, Liposomal Grb-2 ("L-Grb-2" or "BP-100-1.01"), currently in clinical trials. The Company was founded with technology from The University of Texas, MD Anderson Cancer Center ("MD Anderson") and is dedicated to developing novel cancer drugs under an exclusive license arrangement. The Company has drug delivery platform technology with composition of matter intellectual property for systemic delivery of antisense. Bio-Path also plans to investigate developing liposome tumor targeting technology, which has the potential to be developed to augment the Company's current delivery technology to improve further the effectiveness of its antisense. In addition to its existing technology under license, the Company expects to maintain a close working relationship with key members of the MD Anderson staff, which has the potential to provide Bio-Path with additional drug candidates in the future. Bio-Path also expects to broaden its technology to include cancer drugs other than antisense, including drug candidates licensed from institutions other than MD Anderson.
Our business plan is to act efficiently as an intermediary in the process of translating newly discovered drug technologies into authentic therapeutic drug candidates. Our strategy is to selectively license potential drug candidates for certain cancers, and, primarily utilizing the comprehensive drug development capabilities of MD Anderson, to advance these candidates into initial human efficacy trials (Phase IIa), and then out-license each successful potential drug and/or the drug delivery technology to a pharmaceutical company or, if the final steps to commercialization are within the capabilities of the Company, finalize development and commercialization internally.
The Company was founded in May of 2007 as a Utah corporation. In February of
2008, Bio-Path completed a reverse merger with Ogden Golf Co. Corporation, a
public company traded over the counter that had no current operations. The name
of Ogden Golf was changed to Bio-Path Holdings, Inc. and the directors and
officers of Bio-Path, Inc. became the directors and officers of Bio-Path
Holdings, Inc. Bio-Path has become a publicly traded company (symbol OTCQX:
BPTH) as a result of this merger.
Our principal executive offices are located at 2626 South Loop, Suite 180, Houston Texas, 77054. Our telephone number is (832) 971-6616. Our Internet website address is www.biopathholdings.com, and all of our filings with the Securities and Exchange Commission are available free of charge on our website.
Research and Development
Our research and development is currently conducted through agreements we have with MD Anderson. We anticipate that new research and development relationships will be added in the future for pre-clinical testing services and future sites for clinical trials that require multiple sites for patient testing.
Basic Technical Information
Ribonucleic acid (RNA) is a biologically significant type of molecule consisting of a chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate. Although similar in some ways to DNA, RNA differs from DNA in a few important structural details. RNA is transcribed from DNA by enzymes called RNA polymerases and is generally further processed by other enzymes. RNA is central to protein synthesis. DNA carries the genetic information of a cell and consists of thousands of genes. Each gene serves as a recipe on how to build a protein molecule. Proteins perform important tasks for the cell functions or serve as building blocks. The flow of information from the genes determines the protein composition and thereby the functions of the cell.
The DNA is situated in the nucleus of the cell, organized into chromosomes. Every cell must contain the genetic information and the DNA is therefore duplicated before a cell divides (replication). When proteins are needed, the corresponding genes are transcribed into RNA (transcription). The RNA is first processed so that non-coding parts are removed (processing) and is then transported out of the nucleus (transport). Outside the nucleus, the proteins are built based upon the code in the RNA (translation).
Our basic drug development concept is to block the expression of proteins that cause disease. RNA is essential in the process of creating proteins. We intend to develop drugs and drug delivery systems that are intended to work by delivering short strands of DNA material that are inserted into a cell to block the production of proteins associated with disease.
The historical perspective of cancer treatments has been the use of drugs that affect the entire body. Advances in the past decade have shifted to treating the tumor tissue itself. One of the main strategies in these developments has been targeted therapy, involving drugs that are targeted to block the expression of specific disease causing proteins while having little or no effect on other healthy tissue. Nucleic acid drugs, specifically antisense, are a promising field of targeted therapy. Development of antisense, however, has been limited by the lack of a suitable method to deliver these drugs to the diseased cells with high uptake into the cell and without causing toxicity. Bio-Path's currently licensed neutral-lipid based liposome technology is designed to accomplish this. Studies have shown a 10-fold to 30-fold increase in tumor cell uptake with this technology compared to other delivery methods.
Indications for Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia
(CML), Myelodysplastic Syndrome (MDS) and Acute Lymphoblastic Leukemia (ALL)
BP-100-1.01 is our lead lipid delivery antisense drug candidate, which is being clinically tested in patients having Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS) and Acute Lymphoblastic Leukemia (ALL). If the results of the clinical tests are favorable, we expect there will be opportunities to negotiate non-exclusive license applications involving upfront cash payments with pharmaceutical companies developing antisense drugs that need systemic delivery technology.
The Investigational New Drug ("IND") for BP-100-1.01 was submitted to the U.S. Food and Drug Administration ("FDA") in February 2008 and included allin vitro testing, animal studies and manufacturing and chemistry control studies completed. The FDA requested some changes be made to the application submission. We resubmitted information to the FDA in response to such request. On March 12, 2010, we issued a press release announcing that the FDA had allowed an IND for Bio-Path's lead cancer drug candidate liposomal BP-100-1.01 to proceed into clinical trials. The IND review process was performed by the FDA's Division of Oncology Products and involved a comprehensive review of data submitted by us covering pre-clinical studies, safety, chemistry, manufacturing, and controls, and the protocol for the Phase I clinical trial. The primary objective of the Phase I clinical trial, as in any Phase I clinical trial, is the safety of the drug for treatment of human patients. Additional key objectives of the trial are to demonstrate the effectiveness of our drug delivery technology similar to that experienced in pre-clinical treatment of animals and to assess whether the drug candidate test article produces a favorable impact on the cancerous condition of the patient at the dose levels of the study.
The Phase I clinical trial is a dose-escalating study to determine the safety and tolerance of escalating doses of L-Grb-2. The study will also determine the optimal biologically active dose for further development. The pharmacokinetics of L-Grb-2 in patients will be studied, making it possible to investigate whether the delivery technology performs as expected based on pre-clinical studies in animals. In addition, patient blood samples from the trial will be tested using a new assay developed by the Company to measure down-regulation of the target protein, the critical scientific data that will demonstrate that the delivery technology does in fact successfully deliver the antisense drug substance to the cell and across the cell membrane into the interior of the cell where expression of the target protein is blocked. The clinical trial is being conducted at The University of Texas MD Anderson Cancer Center.
The original IND granted by the FDA in March of 2010 allowed the Company to proceed with a Phase I clinical trial having five (5) cohorts culminating in a maximum dose of 50 mg/m 2. However, in November of 2012, the Company announced that since there had been no evidence of significant toxicity from treatment of patients with L-Grb-2, the Company was proceeding with requesting the FDA to allow higher dosing in patients. The Principal Investigator for the clinical trial, in consultation with Bio-Path's Board of Directors, advised that with the absence of any real toxicity barriers, the Company should continue to evaluate higher doses of Liposomal Grb-2. The absence of significant toxicity provides a significant opportunity for the Company to test higher doses in patients in order to find a dose that provides maximum potential benefit and duration of anti-leukemia effect. These actions were approved and a revised protocol is in place allowing higher dosing. The Company announced in June of 2013 that it completed Cohort 5, successfully treating three patients at a dose 60 mg/m 2 , which had been increased from 50 mg/m 2 in the revised protocol. The Company has enrolled three patients in Cohort 6 for treatment at a dose of 90 mg/m 2 and currently has two evaluable patients. The Company is currently awaiting drug resupply to complete Cohort 6.
Patients eligible for enrollment into the Phase I clinical trial have refractory or relapsed Acute Myeloid Leukemia ("AML"), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia ("CML") and Acute Lymphoblastic Leukemia ("ALL"), or Myelodysplastic Syndrome ("MDS") and have failed other approved treatments. These are patients with very advanced stages of the disease, and consequently, not all patients enrolled are able to complete the four-week treatment cycle because of progressive disease, which is unrelated to the treatment with Liposomal-Grb-2.
The Principal Investigator for the Phase I clinical trial, Dr. Jorge Cortes (the "Principal Investigator"), is a leading expert in the treatment of CML, AML, MDS and ALL. In the continuing effort to keep the leukemia oncology community appraised of the development of Liposomal Grb-2, the Principal Investigator submitted an abstract to the American Society of Hematology ("ASH") to be considered for presentation at ASH's annual meeting in December of 2013. The abstract was accepted and a poster updating the progress in the Phase I clinical trial will be presented at the ASH annual meeting. A major part of the update on the Liposomal Grb-2 Phase I trial will be the inclusion of the results of testing of patient blood samples, which demonstrates significant inhibition of the disease causing protein Grb-2. This is a significant development which suggests the potential of Liposomal Grb-2 to inhibit AML and MDS in patients.
Results from the second cohort also demonstrated potential anti-leukemia benefits in treated patients and such results were included in the presentation to the American Society of Hematology. The Principal Investigator is currently preparing an abstract of updated information for presentation at the American Society of Hematology annual meeting in December of 2013.
An important outcome for the Phase I clinical trial is the ability to assess for the first time the performance of the Company's delivery technology platform in human patients. The Company has developed two new assays to be able to provide scientific proof of concept of the delivery technology. The first involves a novel detection method for the drug substance in blood samples that will be used to assess the pharmacokinetics of the drug. The second involves a method to measure down-regulation of the target protein in a patient blood sample that was achieved. The latter measurement will provide critical proof that the neutral liposome delivery technology delivered the drug substance to the cell and was able to transport it across the cell membrane into the interior to block cellular production of the Grb-2 protein.
In this regard, in August of 2013 Bio-Path announced that its liposomal delivery technology achieved a major milestone in the development of antisense therapeutics based on a scientific assay confirming that treating patients with its drug candidate BP-100-1.01 inhibits the Grb-2 disease-causing target protein in patients with blood cancers. Inhibition of the disease-causing protein has the effect of down regulating the disease. This will allow for Liposomal Grb-2 to be used potentially in combination with current frontline treatments. This discovery also points to the potential use of a liposomal antisense treatment as a standalone treatment to transform and manage a disease, which has a disease causing protein, as a chronic disorder. This accomplishment is potentially a significant breakthrough for antisense therapeutics, whose development, to date, as a class of therapeutics has been severely limited by a lack of a systemic delivery mechanism that can safely distribute the drug throughout the body and get the antisense drug substance across the cell membrane into the interior of the cell. Further, we expect that scientific proof of principal for our delivery technology may lead to licensing and business development opportunities, furthering our business model.
Being platform technology, a successful demonstration of the delivery technology in this study will allow the Company to begin expanding Bio-Path's drug candidates by simply applying the delivery technology template to multiple new drug product targets. In this manner, Bio-Path can quickly build an attractive drug product pipeline with multiple drug product candidates for treating cancer as well as treating other important diseases including diabetes, cardiovascular conditions and neuromuscular disorders. Currently, the Company is researching potential targets for which it can apply its liposomal antisense drug delivery technology.
The Phase I clinical trial is typically ended when a maximum tolerated dose (MTD) is encountered. However, due to the lack of toxicity of the drug to date, it is not expected that a MTD will be encountered. As a result, the optimal biological dose will be determined and this dose will be used in the following Phase II clinical trial. The Company plans to evaluate patients at the close of Cohort 6 to evaluate whether the Phase I clinical trial should be ended at that time. It is expected that the down regulation assay will be a factor in the evaluation of whether we have reached optimal inhibition. It is noted, however, that the lack of toxicity is a major advantage for the drug candidate BP-100-1.01 since it allows higher levels of drug to be administered to the patient, increasing the potential therapeutic benefit.
Bio-Path has also been working with the Principal Investigator to finalize plans for Phase II clinical trials in Liposomal Grb-2. Significantly, these plans include three Phase II trials, one each for CML, AML and MDS, of the drug candidate Liposomal Grb-2 in salvage therapy for very advanced patients.
Indications for Triple Negative Breast Cancer (TNBC) and Inflammatory Breast Cancer (IBC)
On July 22, 2013, we announced that we were initiating preclinical testing of BP-100-1.01 into two additional indications: Triple Negative Breast Cancer ("TNBC") and Inflammatory Breast Cancer ("IBC"). TNBC tumors do not express estrogen receptors, progesterone receptors, and low Human Epidermal growth factor Receptor 2 ("HER2"). These negative results mean that the growth of the cancer is not supported by the hormones estrogen and progesterone, or by the presence of too many HER2 receptors. Therefore, TNBC does not respond to hormonal therapy or therapies that target HER2 receptors. In addition, TNBC tumors are very aggressive. Approximately 15 to 20 percent of breast cancers are triple-negative. IBC is a rare and very aggressive disease in which cancer cells block lymph vessels in the skin of the breast. This type of breast cancer is called "inflammatory" because the breast often looks swollen and red, or "inflamed." IBC accounts for two to five percent of all breast cancers. IBC tumors are very aggressive and are frequently hormone receptor negative, which means hormone therapies may not be effective. Five year survival rate for IBC is approximately 40% versus approximately 87% for all breast cancers combined, making IBC a priority area for development of new treatments.
Our plan is to develop BP-100-1.01 as a targeted therapy against TNBC and IBC. Treatment goals are two-pronged: the first being to develop BP-100-1.01 as a tumor reduction agent in combination with other approved drugs in pre-operative settings, and the second is to develop BP-100-1.01 as a drug to treat and control or eliminate cancer metastasis in TNBC and IBC patients. Both of these treatment goals address high need situations for patients. Following successful completion of the preclinical studies, we expect to start a Phase I clinical trial in TNBC and IBC in 2014. We believe that the observations that we learn from the on-going Phase I trial will allow us to progress relatively quickly in such Phase I trial in TNBC and IBC, as the toxicity profile of BP-100-1.01 is currently being established.
BP-100-1.02 ("Bcl-2" or "BP-100-1.02") is Bio-Path's co-lead compound. The scientific name for BP-100-1.02 is Liposomal Bcl-2, a liposome delivered antisense cancer drug that targets the lymphoma and certain solid tumor markets. Liposomal Bcl-2 has the potential to treat 40%-60% of solid tumors.
Bcl-2 is a protein that is involved in regulating apoptosis or programmed cell death. Apoptosis is a physiologic mechanism of cell turnover by which cells actively commit suicide in response to aberrant external signals. Over-expression of Bcl-2 prevents the induction of apoptosis in response to cellular insults such as treatment with chemotherapeutic agents. Bcl-2 is over-expressed in more than 90% of follicular B-cell non-Hodgkins lymphoma due to a chromosomal rearrangement and is the key factor in the initiation of this malignancy. Bcl-2 is also overexpressed in a wide variety of solid tumors (it is estimated to be over-expressed in 40 percent of cancers). For example, Bcl-2 over-expression has been associated with the progression of prostate cancer from hormone dependence to hormone independence and may contribute to the relative drug resistant phenotype typically observed in hormone independent prostate cancer.
Clinical targets for BP-100-1.02 include lymphoma, breast cancer, colon cancer, prostate cancer and leukemia.
Other Liposomal Antisense Products
As noted previously, the Company intends to apply its drug delivery technology template to new disease-causing protein targets as a means to develop new, liposomal antisense drug candidates. A new product identification template was recently approved that defines a process of scientific, pre-clinical, commercial and intellectual property evaluation of potential new drug candidates for inclusion into the Company's drug product development pipeline. A significant amount of capital will be allocated for in-licensing promising protein targets that can be developed as new liposomal antisense drug candidates.
Projected Financing Needs
As of September 30, 2013, we anticipate that we need to raise approximately an additional $6,780,000 to complete our core clinical trials for our product candidates. This includes funds to complete the Phase I clinical trial for BP-100-1.01, one Phase II trial in BP-100-1.01, a Phase I clinical trial for BP-100-1.02, license and patent maintenance costs and general and administrative expense. However, including opportunities for two additional Phase II clinical trials for BP-100-1.01 and a Phase I clinical trial for breast cancer would add the requirement to raise an additional $5,500,000. Consequently, funding all of our opportunities for clinical trials would require us to raise as much as $12,280,000.
The remaining cost of the Phase I clinical trial of BP-100-1.01 is expected to be approximately $300,000, provided that the trial is completed after the next dose level. If the Phase I clinical trial in BP-100-1.01 is successful, we expect to follow with multi-site Phase II trials in BP-100-1.01. Successful Phase I and II trials of BP-100-1.01 are expected to provide clinical evidence to support BP-100-1.01 as a potential therapeutic drug product for treatment of AML, MDS and CML. The Phase II clinical trials in BP-100-1.01 are expected to cost approximately $2,000,000 each, or approximately $6,000,000 for all three to complete the basic treatment for the estimated number of patients.
Development of BP-100-1.01 to treat TNBC and IBC over the 27 month plan horizon is expected to require approximately $1,500,000. This amount is expected to fund the preclinical program and the Phase I clinical trial. It is anticipated that the Phase I clinical trial will cost less than a typical Phase I trial because the safety profile will have already been established upon conclusion of BP-100-1.01's current clinical trial. This is expected to result in fewer patients being tested and a more efficient progression to an optimal biological dose.
The Phase I clinical trial of BP-100-1.02 (L-Bcl-2) is expected to cost approximately $2,000,000. Commencement of the Phase I clinical trial depends on the FDA approving the IND for BP-100-1.02. Success in the Phase I clinical trial will be based on the demonstration that the drug is well tolerated and other key outcomes. The Phase I clinical trial will likely be a dose-escalating study to determine the safety and tolerance of escalating doses of BP-100-1.02. The study will also likely determine the optimal biologically active dose for further development. The pharmacokinetics of BP-100-1.02 in patients will be studied, as well as down-regulation of the target protein to corroborate any positive anti-cancer effects in addition to confirming effectiveness of the delivery technology.
Approximately $200,000 has been allocated to identifying other protein targets for development into liposomal antisense drug candidates. The balance of the $12,280,000 in funding needs from our revised plan over 27 months is approximately $2,080,000, which is planned to fund patent expenses, licensing fees, pre-clinical costs, consulting fees and management and administration. Of the projected total of $12,280,000 in funding needs, approximately $10,000,000 in project costs is projected to be spent on clinical trials of our drug candidates and developing new drug candidates, and the balance is projected to be spent on period costs for professionals, management and license costs.
The scientific evidence that our liposomal delivery technology achieved a major milestone in the development of antisense therapeutics based on a scientific assay confirming that treating patients with its drug candidate BP-100-1.01 inhibits the Grb-2 disease-causing target protein in patients with blood cancers could potentially be very significant in helping to meet future funding needs. The Company envisions that it might be able to enter into licensing/development agreements with potential pharmaceutical company partners seeking systemic antisense drug treatments, which could potentially provide funding from the partner to Bio-Path to develop their liposomal antisense drug candidate, with residual milestone payments and potential back-end royalty payments if the drug candidate became an FDA approved drug. There are many potential licensing/development structures, which would vary in terms of favorability to the Company.
We have generated approximately five full years of financial information and have demonstrated that we have been able to expand our business through an increased investment in our technology and trials. We cannot guarantee that plans as described in this quarterly report will be successful or that we can continue to receive additional capital investment. Our business is subject to risks inherent in growing an enterprise, including, but not limited to, limited capital resources and possible rejection of our new products and/or clinical development methods. If financing is not available on satisfactory terms or at all, we may be unable to continue expanding our operations. Equity financing will result in a dilution to existing shareholders.
There can be no assurance of the following:
(1) That the actual costs of a particular trial will come within our budgeted amount.
(2) That any trials will be successful or will result in drug commercialization opportunities.
(3) That we will be able to raise the sufficient funds to allow us to complete our planned clinical trials.
Background Information about MD Anderson
We anticipate that our initial drug development efforts will be pursuant to our exclusive license agreement with MD Anderson. MD Anderson's stated vision is to "make cancer history" (www.mdanderson.org). Achieving that goal begins with integrated programs in cancer treatment, clinical trials, educational programs and cancer prevention. MD Anderson is one of the largest and most widely recognized cancer centers in the world: U.S. News & World Report's America's "Best Hospitals" survey has ranked MD Anderson as one of the top two best hospitals in the nation since the survey began in 1990. MD Anderson will treat more than 100,000 patients this year, of which approximately 11,000 will participate in therapeutic clinical research exploring novel treatments which is the largest such program in the nation. MD Anderson employs more than 15,000 people including more than 1,000 medical doctors and Ph.D clinicians and researchers, and is routinely conducting more than 700 clinical trials at any one time.
Each year, researchers at MD Anderson and around the globe publish numerous discoveries that have the potential to become or enable new cancer drugs. The pharmaceutical and biotechnology industries have more than four hundred cancer drugs in various stages of clinical trials. Yet the number of actual new drugs that are approved to treat this dreaded disease is quite small and its growth rate is flat or decreasing. A successful new drug in this market is a "big deal" and substantially impacts those companies who have attained it: Genentech's Avastin, Novartis' Gleevec, OSI's Tarceva and Millennium's Velcade are examples of such drugs.
Over the past several years MD Anderson has augmented its clinical and research . . .


text:
Do they work for muscle growth? Anyone use them for training?
I got one prescribed for my lower back injury and it has been helping me these past few weeks. Since I have been out of the gym and curious/bored I have been messing around with putting the pads on different muscle groups. I did not notice a single thing in till I put them on my biceps. I have never had a sicker pump, and it took four days for my arms to fully recover. I did it again yesterday and had to write this post because I am sore as hell again.
I know this can not replace lifting, but I swear I feel like had the best bicep workout ever.
Anyone involve EMS in their routine? Am I sore from fast contractions/twitching or just wasting batteries?
- 24/7 Customer Service 1-877-991-3411
- Contact Us
- Need Help?
- View Cart
Similar Threads

subset: commoncrawl


text:
Each year the Texas Associated Press Broadcasters ("TAPB") recognizes excellence and achievement in journalism with awards in various categories. Your promotion must state the "Texas Associated Press Broadcasters" (NOT Associated Press) as the award's source.
Promotional use of the word "Best" will apply only to first-place winners. Any use of a reference to a TAPB award that in any way misleads the public about a TAPB award, including but not limited to distorted or exaggerated claims, is strictly prohibited. Violations of either the spirit or intent of this prohibition may result in the disqualification of the offending entity from TAPB contests for a one-year period. TAPB board reserves all rights to determine the truthfulness of any promotion that uses a reference to TAPB awards. The TAPB will be the sole determiner of whether or not a violation of this prohibition has occurred.


text:
VMware Images:
Installing Nginx With PHP5 And MySQL Support On Fedora 12 - Page 2
Submitted by falko (Contact Author) (Forums) on Thu, 2010-02-04 17:46. ::
5 Configuring nginx
The nginx configuration is in /etc/nginx/nginx.conf which we open now:
vi /etc/nginx/nginx.conf
The configuration is easy to understand (you can learn more about it here: http://wiki.codemongers.com/NginxFullExample and here: http://wiki.codemongers.com/NginxFullExample2)
First (this is optional) you can increase the number of worker processes and set the keepalive_timeout to a reasonable value:
The virtual hosts are defined in server {} containers. Let's modify the default vhost as follows:
server_name _; makes this a default catchall vhost (of course, you can as well specify a hostname here like www.example.com).
In the location / part, I've added index.php to the index line. root /usr/share/nginx/html; means that the document root is the directory /usr/share/nginx/html.
The important part for PHP is the location ~ \.php$ {} stanza. Uncomment it to enable it. Change the root line to the web site's dosument root (e.g. root /usr/share/nginx/html;). Please make sure that you change the fastcgi_param line to fastcgi_param SCRIPT_FILENAME /usr/share/nginx/html$fastcgi_script_name; because otherwise the PHP interpreter won't find the PHP script that you call in your browser.
Now save the file and restart nginx:
/etc/init.d/nginx stop
(I couldn't use /etc/init.d/nginx restart because this stopped nginx, but failed to start it - don't know why...)
Now create the following PHP file in the document root /usr/share/nginx/html...
vi /usr/share/nginx/html/info.php
Now we call that file in a browser (e.g. http://192.168.0.100/info.php):
As you see, PHP5 is working, and it's working through FastCGI, as shown in the Server API line. If you scroll further down, you will see all modules that are already enabled in PHP5, including the MySQL module:
6 Links
add comment | view as pdf | print: this | all page(s)


text:
Viewing entries tagged with 'intrust super cup'
QRL Intrust Super Cup Teams - Round 1
ALL the teams for the opening round of bumper Intrust Super Cup action thanks to the folks at the Queensland Rugby League.
Channel nine to broadcast Intrust Super Cup in 2012
THE Intrust Super Cup's standing as one of the leading second-tier sporting competitions in the country has been further enhanced today by confirmation that Channel Nine's Wide World of Sports would broadcast live matches on Sundays at 2pm.
Rivalry Round to add spice to QRL Intrust Super Cup
RUGBY league supporters can expect an explosive start to the 2012 Intrust Super Cup season, with an enticing grand final re-match in the opening week to be followed soon after by an electric Rivalry Round in April.
Simpson joins the Tigers
THE Easts Tigers are pleased to announce the signing of utility back Jamie Simpson for the 2012 Intrust Super Cup season.
QRL Intrust Super Cup Grand Final Preview
WYNNUM Manly coach Paul Green admits he's astonished by the fanfare and support for the club as the Seagulls prepare for their first tilt at an Intrust Super Cup grand final...
ISC Preliminary Finals Results
SEE who is progressing to the grand final in the Intrust Super Cup and the Fogs Cup.
QRL Intrust Super Cup Preview - Preliminary Finals
GRAND Final berths are on the line this weekend in the Intrust Super Cup. Here the QRL previews the action for the two preliminary finals.
Intrust Super Cup Semi Finals
RESULTS from the Intrust Super Cup, FOGS Cup and FOGS Colts semi finals.
QRL Intrust Super Cup & FOGS Results - Round 22
A wrap up of the final weekend of the QRL Intrust Super Cup, FOGS Cup and FOGS Colts Challenge, with fixtures for next week's opening week of the Finals Series.
CONFIRMED: Finals Week One - how it works
WE'RE going to try to take the guesswork out of the 2011 Finals Series across the four major grades going into week one next weekend! Read on for who plays who, when and where.
Intrust Super Cup Round 21 Previews
QRL previews for round 21.
QRL Intrust Super Cup Teams - Round 21
ALL the teams for Round 21 of the Queensland Rugby League's Intrust Super Cup, the penultimate round of the regular season.
QRL Intrust Super Cup & FOGS Results - Round 20
ALL the results across the three grades in the Queensland Rugby League from the weekend - Round 20.
QRL Intrust Super Cup Preview - Round 20
FULL preview of Round 20 from the Intrust Super Cup - Queensland Rugby League.
QRL Intrust Super Cup & FOGS Results - Round 19
QUEENSLAND Rugby League results from the weekend's action in QRL Intrust Super Cup and FOGS lower grades.


text:
My cousin, who moved to Indonesia to teach English shortly before I came here, recently updated his Facebook status to something that captured a thought I had but couldn't quite articulate.
"Registered for an absentee ballot; there is something oddly patriotic about living in another nation."
I don't know quite what it is about living in a different country that gives me an intensified sense of patriotism, but I feel it every day. As I make my way through back alleys behind my flat (and past an old, brick wall that any day now is going to collapse — hopefully not on me) to the bus stop, where I board a bus to get to school. As I walk through the school and greet the students with a simple "hello," and they smile and say it back.
I know that our country — particularly its government — has its obvious flaws at times and certainly, its embarrassing and distasteful moments. And there are certain changes that we must work toward if our guaranteed freedoms are ever to be truly realized. But I am proud of the ideas that our country stands for, for the rights that its citizenship allows.
Without my citizenship, perhaps it would not be so easy for me to travel to foreign lands, to learn from different people and to educate myself in new ways. Without it, perhaps I would not be able to be here, right now. Because, although it is a different type of freedom, it is one I am grateful for.
While I am in another country, I have the honor of representing my country to people who may have never met an American before. And I hope to do it justice.
I write this now because it is the week of the 11th anniversary of Sept. 11, 2001. I, of course, like most Americans who remember that day, know exactly what I was doing, and I can remember the tiniest of details about that day. I watched the second plane hit the tower and both towers crumble, live on the news.
This year, on the 11th anniversary of that day, I enjoyed a beer and a cheeseburger with two of the other American teachers here, and we talked about what that day was like for us and the thoughts we have about it.
On the first leg of my journey over here, I flew from Columbus to New York City. It was a small plane, and I do not like flying, for many reasons. A man in the back of the plane had taken a picture of the inside of it on his smartphone. The flight attendant, a man who looked to be in his mid-40s and like something of a badass, saw him and went back to firmly tell him he must delete any images he took of inside the plane. He told him this multiple times and stood there until the pictures were gone.
I don't know why that man took pictures of the plane — probably something as simple as to Tweet about a trip he was embarking on, or to post it to Facebook to see how many "likes" it would get. Maybe he just likes planes.
Then there was the unfortunate thought and assumption that crept into my mind — that he was taking pictures of the inside of the plane to later use for bad things.
I'm not proud of thoughts like that, because I would like to naturally assume the best of people. But thoughts like that are a reminder of the fears that that day brought to life.
Tuesday morning, during my first-hour class, I lead a devotion and prayer.
When I was a 7th-grader on that day, I did not understand its impact. I was not particularly emotional about it, just confused and shellshocked.
During the prayer two days ago, however, I had to fight back the tears.
Again, I can't quite put my finger on what it is about living in another country that makes me feel so patriotic. But I sure felt whatever it was on Tuesday.


text:
Fire leaves 2 families homeless
The American Red Cross says it's come to the aid of two families living in a building damaged by an early-morning fire in St. Johnsbury.
The building was evacuated after the fire broke out Sunday, and several fire departments responded. The Red Cross provided emergency needs of the families that were displaced.
For one family of two adults and a child, financial support was provided to help with food and clothing. For a family of two adults in a second apartment, food, clothing and temporary lodging was arranged.
Copyright 2013 by WPTZ All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


text:
Want to buy this product?
Currently you can buy Paula's Choice products directly from this site and a few top-rated products from other brands are available via links to affiliate websites. We review and recommend products from other brands because we are dedicated to helping you find the best products for your skin, whether they're from Paula's Choice or other lines.
Paula's Choice products are formulated using the same exacting standards we use to review products from other brands.
You have chosen to add to your My Faves.
Optional: You can enter notes about this product below. If you do not wish to add notes, click the 'Add' button.
Peter Thomas Roth makes much ado about (almost) nothing with their Oilless Oil 100% Purified Squalane. While the marketing claims may make squalane seem as if it is a special ingredient, it's as unique as canola oil and from a formulator's viewpoint, no more interesting than dozens of other moisturizing agents.
Squalane is a hydrogenated version of squalene, the latter being the pure component found in plants and animal sources. Squalene is rather unstable, however, and thus squalane is nearly all you'll find in cosmetics (the process of hydrogenation creates the stable squalane). Knowing this, it's a given to say that squalane is purified, as you can't really have it any other way in cosmetic formulas, so Peter Thomas Roth doesn't have an edge here.
The brand makes it clear that the source of their squalane is sugarcane. Why they make such special emphasis on sugarcane isn't exactly clear, as this is no more sustainable than other common plant sources of squalane (like olives), which is the typical source. As long as the world continues to consume olive oil, you'll not need to be concerned with the availability of squalane (but honestly, would you really even consider squalane if Peter Thomas Roth wasn't trying to tell you how special it is?).
If it sounds as if we're being hard on this product, it isn't rated POOR because technically squalane is still a good moisturizing agent. It's just that it's no more special than adding plain olive or grapeseed oil to your moisturizer. It's true that squalane isn't technically "oil", but that differentiation is somewhat pedantic, because many emollients aren't technically oils, but still behave similarly (like jojoba oil isn't technically an oil, it's a wax).
Ultimately, this is just a good, ordinary moisturizing ingredient for dry to very dry skin—consider this (like any non-fragrant plant oil) a fine option to add to your routine for extra moisture. No big whoop.
One last thing, the non-comedogenic claim is rubbish. There isn't any truth to the belief that certain ingredients are incapable of causing breakouts (and the claim that other ingredients are 100% certain to do so). Much of this depends on how much of an ingredient is present in a formula, the overall combination of other ingredients in a product, and numerous external factors.
Oilless Oil 100% Purified Squalane is for anyone looking for all the benefits of an oil without leaving an oily or greasy after feel. It is lightweight, clear, and odorless. Oilless Oil is derived from farmed naturally-sourced sustainable sugarcane (not from sharks or olives). NON-COMEDOGENIC – will not cause breakouts.
Unique in the world of spa and salon specialty lines, Peter Thomas Roth is a large but straightforward line with mostly uncomplicated formulations that, for the most part, are quite good and state-of-the-art. Unlike many product lines, most of the acne, AHA, BHA, sunscreen, and moisturizing products contain what they should to be effective and helpful for skin.
A novel aspect of this line is that there are few (if any) nonsense ingredients. Roth products conspicuously lack the exotic, potentially irritating, sensitizing, and often unnecessary plant extracts and the irritating, fragrant plant oils that show up in most pricey skin-care lines, especially spa lines. Many of these products don't have fragrance, and they lack the long lists of ingredients that are often unnecessarily complicated. Even more impressive are the well-formulated cleansers, sunscreens, AHA products, and skin lighteners. The moisturizers have improved somewhat, and most are now packaged so that the light- and air-sensitive ingredients remain stable. In fact, Roth's packaging deserves special mention because it is exceptionally utilitarian and gender-friendly. No pretty pink bottles, sexy curved jars, or bejeweled caps—all of which reinforce the clinical nature of Peter Thomas Roth. Overall, this line should be admired for its simplicity and, for the most part, for its well-thought-out formulations.
After all that glowing praise there are a few embarrassing missteps to avoid, such as products that contain hydrogen peroxide, which can cause free-radical damage and hurt skin; irritating acne products that contain sulfur; unimpressive masks (odd for a spa-oriented line); and a bumper crop of products claiming to affect expression lines and wrinkles in a manner similar to cosmetic corrective procedures.
For more information about Peter Thomas Roth, call (800) PTR-SKIN or visit www.peterthomasroth.com.
The moisturizers I prefer for my dry skin contain squalane. So I thought, why not try it on its own? It did nothing for me. I far prefer a blend of ingredients that provide lasting moisture over just one oil. This did not make me break out, but everyone is different. For me, Shea butter is a no. I recommend finding the ingredients common to the moisturizers you like before trying a new one - especially a formulation with few ingredients.
This does absolutely cause acne! Do not use this if you are acne-prone! No benefits as far as I'm concerned. A "0"!
Paula Begoun is the best-selling author of 20 books on skin care and makeup. She is known worldwide as the Cosmetics Cop and creator of Paula's Choice. Paula's expertise has led to hundreds of appearances on national and international television including:
View Media Highlights
Iframes Required
The Paula's Choice Research Team is dedicated to helping you find the absolute best products for your skin, using research-based criteria to review beauty products from an honest, balanced perspective. Each member of the team was personally trained by Paula herself.
We respect your privacy and the information you provide will NOT be sold, shared, or disseminated in any way.
Read More →
Call us Mon–Fri 6am-6pm PT, Sat–Sun 8am-4:30pm PT
Connect with us:
© Copyright 2014 Paula's Choice. All rights reserved. Paula's Choice and Cosmetics Cop are registered trademarks of Paula's Choice, LLC.
Our Privacy Policy: We will not sell or share any of the information you provide.
*Promotion expires 9pm PT, December 30, 2014. No cash value. Cannot be combined with other offers or applied to previous purchases.
**Promotion expires 9pm PT, December 30, 2014. No cash value. Applies to US and Canada only.
***Promotion expires 9pm PT, December 30, 2014. No cash value. Cannot be combined with other offers or applied to previous purchases. Limit one free per order while supplies last.
***Promotion expires 9pm PT, December 30, 2014. Choose any 3 from 28 available FREE samples on orders of $5 or more.
Please sign in and access your saved member information.
You will have the option to create an account after you have submitted your order.


text:
val would break starting with JDK8 release
1.8.0_20. Issue #731
@Tolerate; put this annotation on any method or constructor and lombok will skip it when considering whether or not to generate a method or constructor. This is useful if the types of the parameters of your method do not clash with what lombok would generate.
lombok.getter.noIsPrefix, which lets you disable use and generation of
isFoo(), instead going with
getFoo(), for {@code boolean} fields.
IndexOutOfBound: 2 in
ASTConverter.convertType. Issue #686
IllegalArgumentException in the log with message "Path must include project and resource name". Also, 'invalid URL' or 'URI not absolute' errors can occur when using exotic file system abstractions such as Jazz. These bugs haven't been fixed, but instead of catastrophic failure, warning logs will be emitted instead. Issue #682
java -jar lombok.jar config -gv for the complete list.
@Delegate has been moved to
lombok.experimental.Delegate, and corner cases such as recursive delegation (delegating a type that itself has fields or methods annotated with
@Delegate) are now error conditions. See the feature documentation for more information.
@Nullable, on the one parameter of generated
equals() methods by specifying the
onParam= option on
@EqualsAndHashCode, similar to how that feature already exists for
@Setter. Issue #674
canEqual method generated by
@Value and
@Data is now
protected instead of
public. Issue #660
@SneakyThrows with a javac from JDK8 with
-target 1.8 would result in a post compiler error. Issue #655
@Log annotations now support the
topic parameter, which sets the logger's name. The default remains the fully qualified type name of the class itself. Issue #632.
@SneakyThrows annotated methods Issue #438.
@SneakyThrows annotated methods Issue #633.
--format-help for more information. Issue #608
@RequiredArgsConstructor(onConstructor=@__(@Inject)). The old way (single underscore) still works, but generates warnings on javac 8.
@NonNull on an abstract method used to cause exceptions during compilation. Issue #559.
@NonNull on methods that also have
@SneakyThrows or
@Synchronized caused arbitrary behaviour. Issue #588.
@param and
@return are handled appropriately. Addresses feature request Issue #59. @Getter and @Setter documentation. @Wither documentation.
@Value has been promoted from experimental to the main package with no changes. The 'old' experimental one is still around but is deprecated, and is an alias for the new main package one. @Value documentation.
@Builder support. One of our earliest feature request issues, Issue #16, has finally been addressed. @Builder documentation.
@NonNull on a method or constructor parameter now generates a null-check statement at the start of your method. This nullcheck will throw a
NullPointerException with the name of the parameter as the message. Issue #514
Lombok.sneakyThrow() or
@SneakyThrows would sometimes result in invalid classes (classes which fail with
VerifyError). Issue #470
val in try-with-resources did not work for javac. Issue #520
@Data, warnings are not generated if certain aspects are not generated because you wrote explicit versions of them. However, this gets confusing with
equals /
hashCode /
canEqual, as nothing is generated if any one of those methods is present. Now, if one of
equals or
hashCode is present but not the other one (or
canEqual is present but
equals and/or
hashCode is missing), a warning is emitted to explain that lombok will not generate any of the equals / hashCode methods, and that you should either write them all yourself or remove them all. Issue #513
@Value feature no longer implies the also experimental
@Wither. If you like your
@Value classes to make withers, add
@Wither to the class right next to
onConstructor and
onParam to
@Wither, and
@XArgsConstructor. These parameters allow you to add annotations to the methods/constructors that lombok will generate. This is a workaround feature: The stability of the feature on future versions of javac is not guaranteed, and if a better way to implement this feature is found, this feature's current incarnation will be removed without a reasonable period of deprecation. Documentation on the onX feature
@Log4j2 Issue #432
@ExtensionMethods no longer causes
VerifyError exceptions when running eclipse-compiled code if extension methods are called on expressions which are method calls whose return type is a type variable. For example,
someList.get(i).extensionMethod() would fail that way. Issue #436
-Dlombok.disable. This might be useful for code style checkers and such.
NullPointerException in lombok.javac.handlers.JavacHandlerUtil.upToTypeNode(JavacHandlerUtil.java:978) when compiling with
@ExtensionMethod in javac and generated constructors are involved. Issue #423
@Deprecated on a field that gets a generated setter in eclipse would result in
IllegalArgumentException, which you wouldn't see unless you have the error log open. If you have save actions defined, you'd get a popup box with the exception. Now fixed. Issue #408
@Wither and
@FieldDefaults are now available. These are a lot like
@Data but geared towards immutable classes. Documentation on @Value, Documentation on @Wither and Documentation on @FieldDefaults.
@ExtensionMethod. Issue #390
@Cleanup and
@Synchronized cause far fewer issues in the netbeans editor. Issue #393
@ExtensionMethod had all sorts of issues in javac. Issue #399
Class<T>, caused errors. Issue #396
@ExtensionMethod issues in eclipse, such as the ability to call extension methods on a
super reference which is now no longer possible. Issue #406
@ExtensionMethod is now available to add extensions to
any type in the form of static methods that take as first parameter an object of that type. Documentation on @ExtensionMethod
equals and
hashCode. Issue #366
val in an enhanced for loop did not work if the iterable was a raw type.
@Getter(lazy=true) when the data type is boolean, int, array, or some other type that requires special treatment for hashCode/equals, now works properly with
@EqualsHashCode and
@ToString. Issue #376
SneakyThrows in constructor should not wrap this/super call in try-block Issue #381
fieldName as methodname instead of
getFieldName), setters that return
this instead of
void, and support for fields with prefixes is introduced with this lombok version. Also, the number of parameters of any existing methods with the same name that lombok would generate are now taken into account; previously if you had any method named
setX regardless of how many parameters it has, lombok would avoid generating a
setX method. Now lombok generates the method if all present
setX methods have a number of parameters other than 1. documentation.
@Delegate and
@Getter or
@Data will now delegate to the result of a generated getter. Issue #328
java -jar lombok.jar publicApi and including the generated jar in your project. Documentation on using lombok for android development.
@Delegate would generate a method with type parameters of the type
T extends package.Class, a dot would be prepended to the type name. Issue #341
val with a type like
Outer<TypeArgs>.Inner now works. Issue #343
@Getter(lazy=true) where the variable type is a primitive and the initializing expression is of a different primitive type that would type coerce implicitly, i.e. ints can be assigned to longs without a cast, didn't work before. Issue #345
val is no longer legal inside basic for loops (the old kind, not the foreach kind). These variables should rarely be final, and in practice it wasn't possible to delombok this code properly. Issue #346
@Delegate can now be used on a no-argument method, which works similarly to adding it to fields. See documentation.
@Data was present. Issue #51
@Data was present. Issue #222
@Data in certain cases. Issue #301
log field from
@Log, etc, now works in static initializers. Issue #295
@Setter fields. Issue #263
lombok.val would cause NPEs in javac. Issue #299
lombok.val out in full (vs. using an import statement) did not work in eclipse. Issue #300
@NotNull as an annotation that indicates lombok should generate nullcheck guards causes all sorts of problems. This has been removed again, and documentation has been updated to reflect this. Issue #287
@EqualsAndHashCode or
@Data did not work on non-static inner classes whose outer class has a type variable. It does now. Issue #289
@Delegate in eclipse could cause memory leaks in 0.10.0. Issue #264
@AllArgsConstructor was erroneously generating a parameter and an assignment for final variables already assigned in their declaration. Issue #278
@NotNull is now also recognized as an annotation indicating that lombok should generate nullcheck guards in generated constructors and setters. Issue #271
@Slf4j, etc. annotation. More…
@SneakyThrows no longer requires a runtime dependency on lombok.jar. In fact, any call to
Lombok.sneakyThrows(ex) is optimized at the bytecode level and no longer requires you to actually have lombok.jar or lombok-runtime.jar on the classpath.
isFoo or
hasFoo. Now the setter generated for this will be called
setFoo (as the property name is
foo) and not
setIsFoo. Also,
hasFoo is now no longer special; the names would be
isHasFoo and
setHasFoo. The java bean spec does not give
has special meaning.
@EqualsAndHashCode (and by extension,
@Data) now add a
canEqual method which improves the sanity of equality amongst a hierarchy of classes. More…
@Getter now supports a
lazy=true attribute. More…
@Cleanup Issue #154
NullPointerException in Eclipse on the
getTypeBinding method in the error log has been fixed. Issue #164
@Setter and
@Getter can now be applied to static fields again (was broken in v0.9.3 only). Issue #136
hashCode and
canEqual will be generated. Issue #240
@Getter or
@Setter to a class is now legal and is like adding those annotations to every non-static field in it. Issue #129
@RequiredArgsConstructor and
@AllArgsConstructor have been added. These split off
@Data's ability to generate constructors, and also allow you to finetune what kind of constructor you want. In addition, by using these annotations, you can force generation of constructors even if you have your own. Issue #79
@java.beans.ConstructorProperties annotation. This does mean these constructors no longer work in java 1.5, as this is a java 1.6 feature. The annotation can be suppressed by setting
suppressConstructorProperties to
true in a
@RequiredArgsConstructor or
@AllArgsConstructor annotation. Issue #122
equals and
hashCode methods will now use
this.getX() and
other.getX() instead of
this.x and
other.x if a suitable getter is available. This behaviour is useful for proxied classes, such as the POJOs that hibernate makes. Usage of the getters can be suppressed with
@ToString/@EqualsAndHashCode(doNotUseGetters = true). Issue #110
@CheckForNull is now copied from a field to a setter's parameter and the getter method just like
@Nullable. Issue #128
@SneakyThrows: Resolving types in annotations now works better especially for classes that aren't in the core java libraries. Issue #88
tools.jar isn't found (required when running delombok), now a useful error message is generated. The search for
tools.jar now also looks in
Outer.Inner instead of just
Inner. Issue #133
this.fieldName). For those who have a warning configured for unqualified field access, those should no longer occur. Issue #48
@SuppressWarnings("all") attached to avoid such warnings as missing javadoc, for those of you who have that warning enabled. Issue #47
@Data and other annotations now don't throw errors when you include fields with bounded wildcard generics, such as
List<? extends Number>. Issue #84
import lombok.AccessLevel;. In netbeans, that import will no longer be flagged erroneously as being unused. Issue #100 and Issue #103
import lombok.*; is supposed to work in the vast majority of cases. In eclipse, however, it didn't. Now it does. Issue #102
@Getter or
@Setter is applied to a multiple field declaration, such as
@Getter int x, y;, the annotation now applies to all fields, not just the first. Issue #54
<?> style wildcards anywhere in the source, as well as at least 1 lombok annotation. No longer. Issue #134
java -jar lombok.jar --help to see them. Included (aside from the already mentioned delombok):
java -jar lombok.jar createRuntime --help for more information.
java -jar lombok.jar install --help (or
uninstall, of course) for more information. Technically this support has been there in earlier versions, but the command line options are now much more lenient, not to mention more visible.
Throwable.class but it didn't do anything in javac. Issue #73
setURL already exists, then a
@Data annotation on a class with a field named
url will no longer also generate
setUrl. Issue #75
java -jar lombok.jar install eclipse path/to/eclipse) which also supports
uninstall of course. You can now also point at
eclipse.ini in case you have a really odd eclipse install, which should always work.
@Data annotated classes.
@Data can make was being generated as package private when compiling with javac. Issue #63
AccessLevel.NONE that you can use for your
@Getter and
@Setter annotations to suppress generating setters and getters when you're using the
@Data annotation. Address Issue #37
@EqualsAndHashCode and
@ToString now support explicitly specifying the fields to use, via the new 'of' parameter. Fields that begin with a '$' are now also excluded by default from equals, hashCode, and toString generation, unless of course you explicitly mention them in the 'of' parameter. Addresses Issue #32
@NotNull annotation, from javax.validation (and in earlier versions of hibernate, which is the origin of javax.validation) which does not quite mean what we want it to mean: It is not legal on parameters, and it is checked at runtime after an explicit request for validation. As a workaround, we've removed checking for any annotation named
NotNull from the nonnull support of lombok's generated Getters, Setters, and constructors. Issue #43
@SneakyThrows. This was reported fixed in v0.8.4. but it still didn't work quite as it should. Still falls under the bailiwick of
Issue #30
@SneakyThrows - in previous versions, using it would sometimes confuse the syntax colouring, and various constructs in the annotated method would cause outright eclipse errors, such as beginning the method with a try block. This also fixes Issue #30
NullPointerException at lombok.javac.apt.Processor.toUnit(Processor.java:143)
-javaagent parameter is now written as an absolute path in
eclipse.ini instead of a relative one. For some reason, on at least 1 linux installation, an absolute path is required to make javaagent work. This 'fix' has the unfortunate side-effect of making it impossible to move your eclipse installation around without breaking the pointer to the lombok java agent, so this change has only been introduced for non-windows, non-mac. Thanks to WouterS for spotting this one and helping us out with some research on fixing it. Issue #6


text:
Eva LongoriaNo need to commit to a bob when you can just fake it. By folding the hair under and pinning it up, the illusion of a cropped coif is achieved. Mrs. Parker keeps it pinned up in back and lets loose in front.
Red-Carpet Hair: Try on your favorite star stylesRead MoreLess


text:
Word Becomes Flesh
Marc Bamuthi Joseph/The Living Word Project
Presented as a series of performed letters to his unborn son, Word Becomes Flesh uses poetry, dance and live music to document nine months of pregnancy from a young single father's perspective. These performed letters incorporate elements of ritual, archetypes, and symbolic sites within the constructs of hip hop culture.
Friday, March 22 at 8:00 pm
Saturday, March 23 at 8:00 pm
Sunday, March 24 at 3:00 pm
$25 – Advance
$30 – Door (Day of performance)
$15 – Student
Buy Tickets to Word Becomes Flesh.
Word Becomes Flesh (2011) excerpts from MAPP International on Vimeo.


text:
In the highly competitive real estate market, it's not always easy to distinguish yourself from other vendors and brokers. But with a real estate video in HD, you will set yourself apart from the rest. Linkman works with cutting edge video technology to make real estate videos that truly impress.
A Steadicam is a special kind of camera, operated by a Steadicam operator, that allows for fluent 'walking recordings'. This results in a unique and smooth HD video production that truly focuses the viewer's attention on the property.
The Octocam is a flying camera for spectacular arial views in HD. Octocam images are truly amazing in that they show the surroundings of the property and they will give your video an extra premium feel.
Our video approach is also a great sales tool for commercial real estate projects. Service flats, hotels, retail projects like shopping mals, industrial buildings...
This video is a sales tool for Sint Jacobsmarkt in Turnhout (Belgium).
Are you selling a property that is yet to be built? No problem: we can produce a professional 3D animated video to show to potential buyers. When actual viewing of a house is impossible, a 3D HD animated video is the closest you can get!


text:
25 Things People With Short Term Memory Problems Will Understand.
Aren't you supposed to be doing something right now?
Aren't you supposed to be doing something right now?
Jonny Lim a few minutes ago
You're welcome.
pleasewatchclickhere a half hour ago
Eat the apple. Prevent the tears.
ItRhymesWithParis an hour ago
Backstreet's back, alright!
Chloe F. 2 hours ago
You may be a redneck if you ace this quiz!
binkylikenobodyiswatching 4 hours ago
You know it!
emp 4 hours ago
Ho ho hold on for dear life.
EmmaSturgis 4 hours ago
If This Was The End, I know I'd want to spend my last few hours with the multi-hypenate genius we all know and love.
Marisa Diamond 4 hours ago
"Here, wear this panda onesie and eye- fuck the camera." -Forever 21 photographer
Chelsea Cloud 4 hours ago
New York City is full of cute independent shops with gifts you just can't find anywhere else. Pop by this weekend and bring home something special from the big apple this year.
Toddley 4 hours ago
"What greater gift than the love of a cat," Charles Dickens once wrote. No really, what greater gift? Tell us.
Jennifer Schaffer 6 hours ago
Each kitty deserves a home! These kitties are available for adoption from the Los Angeles STRAY CAT ALLIANCE! Each cat has a different story and could be YOUR new cuddle buddy! Pre-Order a #CatLoversTee and 25% will go the SCA in Jan 2015!
alexinhwood 6 hours ago
This episode aired 14 years ago. Feel old.
Stacey Grant 6 hours ago
The holidays bring out the best in people.
GinnyIsaad 6 hours ago
Nowadays when the fashion world and the reptilian world are becoming ever so overlapped, it is good for us to practice differentiating from the two. Thanks to Mario Batali's help, this quiz is here to help you do just that!
jefstathiades 7 hours ago
We're all mad here.
missalissa 7 hours ago
Draking and Vining.
Lea Ryan Monroe 7 hours ago
The food industry utilizes a full arsenal of psychological tricks, smoke and mirrors, and out right deception to sell food. One tactic, food labels, aims to make us think unhealthy foods are healthy and make us feel better about the treatment of animals. If these labels told the truth, here is what they would say.
beltzy 7 hours ago
You're looking a little jealous over there.
emleschh 7 hours ago
These dudes are just chill enough to attend the festivities honoring Everyone's Favorite Stoned Wizard.
mikesetaro 7 hours ago
U.S. President Barack Obama announced today that the U.S. and Cuba will re-establish diplomatic relations, ending their half century Cold War standoff. A huge and extremely important moment for both countries. Crying ensued.
adefillo 7 hours ago
Could you take on the ultimate challenge? Philips has partnered with XCOR Space Expeditions to take one lucky person to space with us. Enter our competition to win your place. Here's some inspiration from our furry friends who are definitely up for a challenge…
Advertiser PhilipsMenUK 7 hours ago
Dia-badasses. Represent.
aleximelvin 8 hours ago
These are some real stinkers.
Michelle Regna 9 hours ago
We can't all be Elf.
LaliLada 9 hours ago
Ten gratuitously graphical representations of the sex acts recently banned from UK porn. Sure to have landmark ramifications for all.
Xavier Toby 9 hours ago
Essentially, this is the sequel to Jingle Bell Rock.
JamesHarness 10 hours ago
Dear Diary, Will you marry me?
CarpeLibrumLibra 10 hours ago
That is, if you don't believe in Santa…
Spencer Althouse 10 hours ago
EMAIL email@example.com
TWITTER @arielle07
EMAIL firstname.lastname@example.com
TWITTER @catesish
EMAIL email@example.com
TWITTER @SpencerAlthouse
EMAIL firstname.lastname@example.com
TWITTER @fanaticalscribe
EMAIL firstname.lastname@example.com
TWITTER @AndrewDZiegler
EMAIL firstname.lastname@example.com
TWITTER @LorynBrantz
EMAIL email@example.com
TWITTER @BrettSVergara


text:
Delkin 16GB SDHC UHS-I 400x Memory Card, 65MB/s Read, 41MB/s Write Speed
Ways to Save
Why Adorama?Easy Returns, Fast Shipping, Trusted for over 35 years.
Need help? Call 800-223-2500 212-741-0052
Our Price$9.95 Add to Wishlist
Get the best value shopping our selection of used gear.Shop Used
We Pay top dollar for your used photo & video equipment.Get A Quote
Need help? Call 800-223-2500 212-741-0052
Our Price$9.95 Add to Wishlist
The Delkin 16GB SDHC UHS-I 400x Memory Card has 16GB of data storage capacity for photos, videos and other files. It supports HD and 3D video recording, as well as high-speed RAW shooting. The card carries Delkin's Better rating, meaning it's been specifically designed for faster read and write speeds, in order to achieve improved performance during HD video and RAW image capture and when using advanced modes like slow motion recording. The card's 400x speed rating and Ultra High Speed Class 1 (UHS-I) designation enable it to support read speeds of up to 65MB/s and write speeds of over 41MB/s.
|Card Type
|Class Rating
|Speed Rating
|Read Speed
|65 MB/s max.
|Write Speed
|Over 41 MB/s


text:
'Red' alert: Bloodhound helps firefighters on search-and-rescue missions
BY SUSAN DEMAR LAFFERTY Sun-Times Media August 25, 2013 10:58PM
Article Extras
Updated: September 27, 2013 6:33AM
When a 10-year-old New Lenox girl with autism was reported missing recently, Red quickly found her in a hiding spot three blocks from her family's home.
All he needed was a whiff of the T-shirt she had slept in the night before. He put his wrinkled face to the ground and followed her scent, leading rescuers to a brushy area.
Red, a New Lenox firehouse's bloodhound, was just doing what he does best.
"He certainly makes search-and-rescue missions a lot easier," said firefighter Greg Gaj, one of Red's handlers with the New Lenox Fire Protection District.
Red was rescued from a shelter by firefighters .
He is the only search-and-rescue hound in Illinois who lives at a fire station, and maybe one of a few in the country, Fire Chief Jon Mead said.
Most are kept by police departments, including the Cook County sheriff's office, Gaj said.
"When they said they wanted a dog, I told them it has to do something, not just lay around," Mead said. Red had to meet all three shifts of firefighters on duty at the station before they could adopt him.
"He was rescued and he became a rescuer," the chief said. "One dog can do the work of 100 people."
When firefighters found this 1-year-old bloodhound, who already was named Red, it seemed the perfect match. He was real skinny when he first came to the firehouse, but now he is a proud, healthy, laidback dog who loves to hang out on the picnic tables in the firehouse parking lot. And he occasionally finishes their food if they forget to cage him before leaving on a call.
Gaj and fellow firefighter/paramedic Frank Hasik — both dog lovers — volunteered to be Red's handlers. A third firefighter, Ryan Mallary, is in training, so one of the handlers will be available 24 hours a day.
"It seemed like a cool thing to do," Hasik said.
Red and his handlers are certified by the National Police Bloodhound Association and are to travel to New York every May for a 40-hour certification course. Red also trains every other week with other bloodhounds from neighboring police departments, and for about an hour a day at the fire station.
Red is laidback until they tell him it's time to go to work; then he gets fired up.
"When his harness is put on him, he knows it's time," Gaj said. "He's a slow-moving dog, so he doesn't miss much."
As Gaj and Hasik have learned, bloodhounds are the perfect hunting dogs. Red's olfactory system is "a million times better than a human," Gaj said. His long ears help sweep up the smells as he wrinkles up his face to trap the odors, and keeps his nose to the ground, as Red demonstrated by tracking a visitor to the fire station.
His handlers watch to see which way he is going. When he gets close to his target, he gets real excited.
Red has tracked down a burglary suspect; found a drunken driver who ran into a cornfield after a crash, and traced a missing teen who left an underage drinking party and hopped a train. Red traced the teen's scent to the train station, and authorities found the teen when he arrived at Union Station in downtown Chicago, Gaj said.
"Everybody sheds skin cells. Every person leaves a trail," Gaj said.
Red has had advanced training, in which he has learned to follow a trail in water, too.
Around the firehouse, he has been the perfect pet, protecting his turf and barking when strangers approach.
He loves attention and socializes well with children.
When the tones and sirens go off, he knows it's time to get in his cage.
When he's not in training, Red might be digging a hole, eating or — more typically — sleeping, firefighters said.
He makes the rounds at night, getting petted and hugged by everyone on duty, but he's partial to his handlers, often greeting them when they return from a call.
"He's a great stress reliever, with a goofy face that you just love," Hasik said. "He's been a real good dog for us. We got lucky."
The community has embraced Red as well, welcoming him into schools. The Doggie Salon has provided free grooming, and Carey Animal Clinic offers vet services at greatly reduced rates, Hasik said.
"We're happy to have him," Mead said.
Finding that 10-year-old girl was one of Red's best assignments.
"It was a great outcome," he said.
"He is the perfect firehouse dog," Lt. Dennis Randolph said. "If we could just get rid of the drool."


text:
Event Date 1: October 12, 2010 01:00 pm
U.S. Under Secretary of Education Martha Kanter will address community-based college advisers at the annual conference for National College Access Network (NCAN) on Tuesday, Oct. 12 at 1 p.m. The event will be held at the Washington Hilton in Washington, D.C.
The Under Secretary will discuss the Administration's college access and success initiatives and the ways that community-based organizations can be more involved. NCAN is an organization that aspires to build, strengthen and empower communities committed to college access and success so that all students, especially those underrepresented in postsecondary education, can achieve their educational dreams. Its members provide advising services to students and their families, among others.
Event 1
|Who :
|U.S. Under Secretary of Education Martha Kanter
|What :
|Remarks at National College Access Network's annual conference
|When :
|1 p.m. on Tuesday, Oct. 12
|Where :
|Washington Hilton
International Ballroom Center
1919 Connecticut Ave. NW
Washington, D.C.


text:
The-Dream readies Love IV for 2013 release
Use your ← → arrow keys to navigate
1 of 1
published7 Dec 2012
The long-awaited album is due out in March.
With 2012 winding down, it appears the "MMXII" has been removed from the title of Love IV, the next full length from the R&B superproducer. The-Dream says Love IV was pushed back due to his production duties on Rihanna's Unapologetic (he co-produced 'Phresh Out the Runway', 'Love Without Tragedy / Mother Mary' and controversial Chris Brown duet 'Nobody's Business') and has been involved with Beyoncé's forthcoming fifth album.
Billboard reports that The-Dream previewed some songs from the album last March, including the sex jam 'Foreplay' and Gucci Mane collaboration 'Paid'. On December 18, the 1977 mixtape will be commercially released as Terius Nash: 1977 and credited to The-Dream.
1 of 1
"Monogamy's like trying to redo biology": r'n'b hit machine The-Dream on sex, lies and why sometimes it pays to be a jerk


text:
A Perfect Getaway
In Theaters
Cliff and Cydney (Steve Zahn and Milla Jovovich) are an adventurous young couple celebrating their honeymoon by backpacking to one of the most beautiful, and remote, beaches in Hawaii. Hiking the wild, secluded trails, they believe they've found paradise. But when the pair comes across a group of... more
Rate it:
Rated R
Photo Albums
click pictures to view full album
more pictures
Seen it? Like it?
- Gabriella Baker says "Looking For a Movie Recommendation? Visit Us &......" more


text:
Find A Physician
Return to Cancer: Overview Overview
More on Cancer: Overview
Hospital News
Return to Cancer: Overview Overview
More on Cancer: Overview
- Dr. Lewis Cantley Awarded $3 Million Breakthrough Prize in Life Sciences for Excellence in Cancer Research
- Top Blood Cancer Team Joins NewYork-Presbyterian Hospital/Columbia University Medical Center
- New Program for Cancer Patients
- Weill Cornell Medical College and NewYork-Presbyterian Hospital Announce New Powerhouse Recruit for Cancer Research and Patient Care
- Dr. Andrew L. Kung Named Director of Pediatric Hematology, Oncology and Stem Cell Transplantation
- American Association for Cancer Research Honors Dr. Andrew Dannenberg With Its Prevent Cancer Foundation Award for Excellence in Cancer Research
- Family History of Breast Cancer May Raise Risk for Ovarian Cancer
- The Endangered Future of the Physician-Scientist
Health Library
Research and Clinical Trials
Return to Cancer: Overview Overview
More on Cancer: Overview
Clinical Services
Cancer: Overview
Overview of Cancer
What is cancer?
It is the nature of cells to divide and increase their number in a process called mitosis. Normal cells divide to replace those lost, or to repair injuries only, then stop dividing.
Cancer is an abnormal, continuous multiplying of cells. The cells divide uncontrollably and may grow into adjacent tissue or spread to distant parts of the body. The mass of cancer cells eventually become large enough to produce lumps, masses, or tumors that can be detected, which can be benign or malignant:
- benign tumors:
- are not cancerous
- can usually be removed
- do not come back in most cases
- do not spread to other parts of the body, and the cells do not invade other tissues
- malignant tumors:
- are cancerous
- can invade and damage nearby tissues and organs
- metastasize (cancer cells break away from a malignant tumor and enter the bloodstream or lymphatic system to form secondary tumors in other parts of the body)
The smallest cancer that can be detected by examination, x-ray, or scan is slightly less than one-fourth of an inch in diameter and contains between a million to a billion cancer cells.
What are the general categories of cancers?
There are several general categories of cancer, with carcinomas and adenocarcinomas being the most common:
- Carcinomas - are cancers that occur in epithelial surfaces - the cells that form the outer surface of the body to line or cover the body's cavities, tubes and passageways.
- Adenocarcinomas - are cancers that form on a glandular surface, such as the lung, breast, prostate, ovary, or kidney.
- Sarcomas - are cancers that occur in supporting structures, such as bone, muscle, cartilage, fat, or fibrous tissue.
- Leukemias and lymphomas - are cancers that occur in blood cell elements.
Brain cancers, nerve cancers, melanomas, and certain testicular and ovarian cancers do not fall into a general category.
What are primary cancers?
Cancers begin in a single cell, and that cell is the site of the primary cancer. The cancer is named for the primary site of origin, such as skin, colon, or breast. For example:
- When cancer is found in the liver that originated in the colon it is called colon cancer that has metastasized to the liver, not liver cancer.
- Liver cancers are those that originated from a liver cell. If it spreads to the lung, it is still liver cancer, not lung cancer.
- When cancer spreads to the regional lymph nodes, those nodes are said to contain metastatic cancer. (Cancers that originate in the lymph cells of a node are called lymphomas.)
What are metastatic cancers?
Cancer can spread from its original location to other parts of the body.
- Spreading may occur by direct extension or invasion into adjacent tissues.
- Systemic spread throughout the body may occur by way of the:
- blood system - arteries and veins take blood to and from all areas of the body
- lymphatic system - a network of lymphatic vessels in all areas of the body that drain and filter infectious agents
- cerebrospinal fluid
When cancer spreads to another part of the body, it is called metastatic cancer.
Click here to view the
Online Resources of Gynecological Health


text:
At the end of the program successful students will be able to:
Effectively use a variety of computer software to accomplish office tasks.
Apply mathematics concepts to typical business situations.
Effectively communicate orally and in writing in the context of common business practices.
Design, maintain and evaluate office systems (paper flow, mail procedures, records management, etc.)
Define, explain, correctly spell, and effectively use business terminology.
Effectively apply components of the accounting equation to typical business transactions.
Work as a team member in an office environment to accomplish the goals of the organization... and more.


text:
Owned by our farm families in New York & New England — Since 1919
If you can't find what you're looking for, ask your local store manager to begin carrying Cabot products.
Percent Daily Values are based on a 2,000 calorie diet.
Your daily values may be higher or lower depending on your calorie needs.


text:
Slippery roads only part of the problem
With the weather being somewhat questionable through the early morning hours, I figured that this would be the overnight where things turned extremely busy.
Wrong again.
There was a call around midnight for a car having been driven into the railroad overpass on Joseph Avenue in downtown Rochester. Because it was snowing at a pretty good clip at that time, it seemed fairly likely that slippery roads played a role in the accident.
Wrong again.
There was in fact, an accident. A car had been driven head-on into the railroad overpass and there was plenty of damage to the vehicle. Those railroad overpasses do not have a lot of give in them, it seems.
Again, in a sure sign that things have been slow overnight, within two minute's time, the newspaper guy and two TV guys pulled into the parking lot at the Amtrak station to check out whether the accident was worth shooting on video.
It turns out that the wreck was caused by an alleged drunk driver, which was a somewhat apropos because the point of impact was immediately beneath a giant billboard advertising a popular choice of rum.
The driver was undergoing a sobriety test as we walked up, and unluckily for her, she did not appear to pass the test.
She was actually fortunate that she could walk at all, at least in the opinion of a tow-truck driver who was hauling away the damaged vehicle. He said that the driver hit the overpass so hard that it crumpled the floorboards in the vehicle. He also mentioned that he was picking up the vehicle's transmission piece by piece, and parts of the car littered the road underneath the overpass.
About 6:30 this morning, there was a multi-vehicle crash underneath the 441overpass on eastbound I-490. Fortunately, there were no serious injuries.
Not a whole lot is truly frightening about this job, but I am most uncomfortable having to take video or photos on the side of the expressway — at any time of day or night. When the roads are slick, it makes it even worse.
The other problem is that I have been negligent in purchasing a high-visibility vest to wear to these incidents. A law went into effect around Thanksgiving that basically says that people — including journalists — have to wear these vests while working along the highway.
I think it is up to about 32 times that I have reminded myself that today is the day I have to go get one, and I have managed to forget each and every time.
This morning, thankfully, I was able to borrow one from colleague Victoria Freile.
When I returned, I told Victoria that I had not actually gone to the accident scene, but had worn her vest for the "Fat Guys of the Overnight" charity calendar that will be on sale everywhere very soon.
There is little doubt that the calendar — and the vest — will be a big, BIG hit.


text:
Man sentenced to prison in killing of Essence Willoughby
Updated On: Jan 03 2014 03:08:15 PM CST
A Jackson County judge sentenced a man Friday to 25 years in prison in the killing of Essence Willoughby.
As part of a plea agreement, Ja A. Ray, 43, will have to serve at least 85 percent of his sentence for second-degree murder.
Prosecutors said in a news release that Ray also was sentenced to seven years in prison on a pending drug possession charge and five years for a 2010 domestic assault that involved Willoughby, 21. All sentences will run concurrently.
Willoughby's body was found in November 2012 after her 3-year-old son led police to it in a wooded area near the intersection of Leeds Trafficway and Stadium Drive.
Copyright 2014 by KMBC.com. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


text:
Hot Hitters
Mike Moustakas:Â 25 AB, .520 AVG, 1.320 OPS, 2 K
Moustakas is one of many hot hitters for the 11-0 Royals. He hit for more power last year than he did in his rookie campaign, but increased strikeouts hampered his productivity. Bringing his contact rate up is as much of a positive sign as the high batting average.
Brandon Belt:Â 25 AB, 3 HR, .480 AVG, 1.140 OPS, 3 K
He keeps making progress, but generally slower than the Giants or his fantasy owners would like him to. Even with Aubrey Huff out of the picture there are still playing time concerns. His OPS last spring was also over 1.000 but he slumped once the games started counting before rallying with a strong second half. He may not be OF-eligible in some formats this year, putting more pressure on his bat.
Nolan Arenado:Â 17 AB, 4 HR, .412 AVG, 1.647 OPS, 1 K
His prospect status took a hit last year as he under whelmed in Double-A. He still projects as Colorado's future third baseman, and a strong Spring could accelerate the timetable. There is a hodgepodge group blocking him and any injury could open up an opportunity.
Cold Hitters
Kirk Nieuwenhuis:Â 18 AB, .056 AVG, .206 OPS, 7 K
He is resting a bruised knee for a few days, and will hopefully figure out why he cannot buy a hit. Â He played 91 games for the Mets last year and has the inside track for the center field job, but could find himself on the bench more than expected depending on how the team values Spring Training performance.
Dan Uggla:Â 23 AB, .259 OBP, 3 BB, 12 K
Last year he set a career low with a 70.1% contact rate and he does not appear to have made any adjustments. The soon to be 33 year-old has job and contractual security, but could be hard pressed to deliver much more than league average offensive production.
Darin Ruf:Â 23 AB, .130 AVG, 2 BB, 6 K
A feel-good story last year, the late bloomer is experiencing some adversity. Between a cold bat and unflattering defensive adventures he is playing himself onto the bench. His ability to slide to first base should be enough to keep him on the roster.
Hot Pitchers
Rick Porcello:Â 8.0 IP, 7 H, 0 BB, 10 K
This is quite an improvement from a pitcher that has not averaged over 5.5 K/9 and has a career 2.13 K/BB. If nothing else this start should allow him to beat out Drew Smyly for the fifth starter's position. That would also put an end to the mostly idle speculation of him becoming a closer.
Al Alburquerque:Â 5.0 IP, 2 H, 4 BB, 10 K
Detroit's bullpen is in some disarray, and Alburquerque could pitch his way into some save opportunities. He always strikes hitters out and is very effective against right-handed batters if the Tigers want to platoon him with southpaw Phil Coke. He needs to improve his control to be a top-notch short reliever.
Jeff Francis:Â 9.0 IP, 0 R, 6 H, 0 BB, 5 K
Francis has much to prove in order for the fantasy community to trust him, but the pitching-needy Rockies will put him on the mound as long as he gets good results. He generated 50.3% ground balls last year, a good feature for any pitcher hoping to succeed in Coors Field.
Cold Pitchers
Jair Jurrjens:Â 5.2 IP, 9 H, 6 ER, 6 BB, 2 K
Non-tendered by Atlanta he resurfaced in an Oriole uniform. He is pitching for the first time since July so perhaps a longer tune up phase is needed. Nothing in his skills profile suggests he can survive in the AL East.
Jonathan Sanchez:Â 3.1 IP, 6 H, 7 BB, 2 K
He is coming off a lost year and establishing some confidence in the spring could have gone a long way towards rejuvenating his career. The opposite has happened and he appears no closer to proving he can succeed in the majors.
Clayton Kershaw:Â 8.0 IP, 17 H, 8 ER, 1 BB, 12 K
The strikeout and walk numbers are the only ones that fantasy players should take interest in. All the rest is just noise. He remains primed for a big year and could be the highest rated pitcher in fantasy when all is said and done.


text:
Throughout the most recent school year, the organization's volunteers visited local schools to help children plant flowers and teach them about environmental issues.
Executive Director Joanne Maskew said, between April 24 and May 15, students and volunteers planted "a little over 3,000" flower seeds.
Board President Shari Horton said she received an email with a photo that showed how one little girl's sunflower had begun to grow. Though she quipped that she was still cleaning the dirt out from under her fingernails, she called the series of school visits a "success."
"The kids just love it," Horton said.
Another project that involved local students was also called successful.
A group of Cleveland High School students under the direction of teacher Jeannie Cuervo recently cleaned up the portion of the Cleveland/Bradley County Greenway near Mohawk Drive.
The students gave up their time, wading through the creek at times to collect about 2,200 pounds of debris, Maskew said.
She added that, while volunteers working with KAB had cleaned up along the Greenway before, this was the first time that portion of it had been cleaned, which accounted for the large amount of debris.
"They did an amazing job," Maskew said.
In addition to the volunteers working with KAB, she said some nearby residents even pitched in to help when they saw people working to improve the Greenway near them.
While students are out of school for the summer, the organization has continued to focus on raising money for educational programs.
The group will host a pancake breakfast at the Applebee's restaurant on Saturday, June 14, from 7 a.m. to 10 a.m. Tickets are $5 and can be purchased at the door.
There is also a yard sale fundraiser that is tentatively scheduled for Oct. 4. The group has been working to secure a location for it and will be looking for donations of items to sell once the event date gets closer.
The board also announced the latest recipients of its two awards — the monthly Business Beautification Award and the quarterly White Glove Award.
The Business Beautification Award is given monthly to a local business or organization exemplifying a commitment to maintaining the cleanliness and aesthetic beauty of its property.
Hopewell Church of God is set to receive the award for the month of June. May's recipient was Larry Hill Ford.
The White Glove Award is given quarterly to a local business or organization that is said to have done an extraordinary job of keeping their community clean through things like maintaining their properties well and following responsible environmental practices.
Brown Stove Works is set to receive the next White Glove Award in June. The most recent one was given to United Knitting during KAB's annual Solid Waste Breakfast in March.
KAB members will give both awards to their recipients in separate ceremonies that will be scheduled at a later date.
For more information about KAB, visit www.clevelandbradleykab.com.


text:
LOG HOME and RIVER FRONT LOTS ON THE YUKON RIVER. - USD 240,000
in the 8/07 issue of popular photography a photo was taken from directly in front of our property (pg 58/59). library & the largest museum in the state, fire station, ems, we have: k-12 school.we are the gateway to yukon charley rivers national preserve.
first floor is fured out log with tongue & groove pine & rigid insulation in the living room & dining room. please call.all new plumbing & paloma hot water on demand (06) new grey water septic & line (07) new water well line put in (08). gold mining equipment may be available. no building/remodeling permits required thus no hidden costs.
good business location for a b&b as well as a riverfront business serving canoists and other travelers from around the globe.electric, phone & hugesnet internet. nice for active retired folks, sportsman, writers/artists, prospectors, historians, and folks who just love a wilderness setting.has base board/boiler heat, paloma hot water on demand, vermont castings defiant wood stove/fireplace and a turn of the century wood cook stove. if you are an artist or crafts person we may be able to arrange for you to buy out our seasonal business thus you can generate some income while still having your winter months free to roam & play.
our property has excellent water (hard to come by in alaska)canadian white spruce log cabin/frame home
located in the heart of gold country on the yukon river in historic eagle city alaska and excellent hunting for grizzlys, moose, caribou & dall sheep, black.trades considered.i have been here since 1981 and can answer just about any question you may have.
real value $331,000 based on current lot values, cost to construct building (estimated by independent source) & to put in two wells & two septics.road is closed mid-oct through mid-april. sheetrock in remainder, second floor is double stud wall framing & sheetrock. has brown metal roof and all metalbestos chimneys. boat & motor may be available as well.
sale includes all major appliances. no building codes, no zoning restrictions. sell/trade can include boat & motor, cuatro wheeler, tools etc.dining room & living room, laundry room, ft which sits high above the river with excellent well/water, kitchen with lots of storage space, first floor is plumbed with full bathroom.second floor has a master bedroom and three additional bedrooms and a room intended to be a bathroom or 5th bedroom, as well as several large storage areas. being located at the end of a 160 mile dirt road has its challenges and advantages. all the other photos are taken from various points on the property.
owner financing available. carpet & linoleum throughout. as one colorful local puts it \"we are not snowed in, everyone else is snowed out!\" travel to & from the nearest city (fairbanks) is via mail plane when the road is closed.
the cabin is a two story log & frame home. also, their is no vandalism. org listing#4236
two riverfront lots (side by side) with a well & two larger lots with cabin, well and two septics (immidately behind the two river front lots.
historic eagle city is a great place. home is fully furnished.
0 taxes - no property, sales, state or land taxes. a well insulated home.nice yard space with large white spruce and birch trees.excellent gardening as well!
owner financing available with large down payment.000 or home on approx uno acre $200, 000 or all the property for $240, 000, properties can be divided: two river front lots & well $50.unattended properties are safe here. fishing for greyling, trout. summers are warm-hot and dry.hunting, other activities available are berry picking, city council member etc, librarian, fishing, hiking, four-wheeling (in fact you can use four-wheelers for all your transportation needs on our gravel roads) and lots of opportunity to volunteer as museum guide.
will sell individually or as a package.or overseas.)
the one plus acre (nearly diez regular city lots) includes a log cabin (in photos).
property located a short distance from state gravel strip with free plane parking or float plane with river parking in front of property. negotiable. 250 gal propane tank, attractive outhouse,
this property includes two 500 gal fuel tanks, 10x12 storage shed.dos gas/garages, dog race. we have uno store, uno laundry, mail is flown in metros-f depending on weather.if your considering summer seasonal living - this is a great location.
alaska residents receive pfds and other state generated income annually.two wells, two septics and more.
will consider trade for the right rural/remote acreage with/without improvements in texas counties edwards, real, etc, uvalde. 1600 sq. we are also located at the mid check point for the yukon quest 1000 mi. spectacular views of the yukon river, ogilvie mountains & eagle bluff from cabin. ft.), great views of the yukon river, eagle bluff & ogilvie mountains. the cuatro lots available together or separately.attic has 24\" insulation. safe, community minded, family oriented. two properties/home available.
please view the slide show .the home is set up to easily drain the plumbing system and close down for the winter (allow to freeze-up).two arctic entries (footage not included in the 1600sq.more interior pictures at goswap.hunting & other riverfront activities in the summer & snowmobiling, cross country skiing, rock collecting, snowshoeing & dog mushing in the winter, wildlife viewing, immediate access to boating, fishing.


text: The MD Brush has an unusual grip that automatically angles the brush head at 45 degrees. Meredith Rizzo/NPR hide caption itoggle caption Meredith Rizzo/NPR Shots - Health News Build A Toothbrush, Change The World. Or Not August 27, 2014 You think bringing a new toothbrush to market is easy? The seven-year saga of two dental entrepreneurs struggling to bring their patented brush to consumers suggests otherwise. Listen Loading… 7:38 Download Playlist